Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
Background
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
“Another TGF-β monoclonal antibody, Fresolimumab (GC-1008), was demonstrated to be safe and well tolerated in Phase I and Phase II trials [261].”
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
EMT: Mechanisms and therapeutic implications
Singh, M., Yelle, N., Venugopal, C., & Singh, S. K. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.009 · Cited by 475
TGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
“Seven patients showed partial response, four developed reversible cutaneous keratoacanthomas and SCCs, and one patient acquired hyperkeratosis as unwanted side effects [106].”
BackgroundCancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
“…fresolimumab (GC1008), which is capable of neutralizing all human isoforms of TGF-β, has also been investigated in advanced malignant melanoma and renal cell carcinoma and showed early stage anti-tumor effects with no dose-limiting toxicity in a phase I clinical study (Morris et al., 2014).”
BackgroundTransforming growth factor‐β in stem cells and tissue homeostasis
Xu, X., Zheng, L., Yuan, Q., Zhen, G., Crane, J. L., Zhou, X., & Cao, X. (2018) · Bone Research · doi:10.1038/s41413-017-0005-4 · Cited by 414
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 402
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
Zhang, N., Ng, A. S., Cai, S., Li, Q., Yang, L., & Kerr, D. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00343-0 · Cited by 349
EMT Factors and Metabolic Pathways in Cancer
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V., & Zaravinos, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00499 · Cited by 349
Complexities of TGF-β Targeted Cancer Therapy
Connolly, E. C., Freimuth, J., & Akhurst, R. J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4564 · Cited by 345
Transforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
“We did not see keratoacanthomas in our study; however, several patients had epistaxis, gum bleeding, or subconjunctival eye hemorrhage, as reported in other studies of fresolimumab (46, 47).”
ResultChapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Self-citationSignal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks
Zhang, J., Tian, X.-J., & Xing, J. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040041 · Cited by 325
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Fresolimumab, a human monoclonal antibody against TGF-β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti-tumor activity in malignant melanoma and renal cell carcinoma [42].”
BackgroundImmune-mediated pathology in Duchenne muscular dystrophy
Rosenberg, A. S., Puig, M., Nagaraju, K., Hoffman, E. P., Villalta, S. A., Rao, V. A., Wakefield, L. M., & Woodcock, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7322 · Cited by 304
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
“Among these, fresolimumab (1D11) [171] and SAR439459 [172] neutralize all three TGF-β homodimers, whereas NIS793 neutralizes TGF-β1 and TGF-β2 but not TGF-β3 [173].”
BackgroundExcessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Grafe, I., Yang, T., Alexander, S., Homan, E. P., Lietman, C., Jiang, M. M., Bertin, T., Munivez, E., Chen, Y., Dawson, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3544 · Cited by 306
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Transforming growth factor-β: a therapeutic target for cancer
Haque, S., & Morris, J. C. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1327107 · Cited by 276
Self-citationTrachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.33 · Cited by 263
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257
“, b1, b2, and b3) with half-life ranging from 21 to 30 days (24).”
BackgroundTargeting TGF-β Signaling for Therapeutic Gain
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 241
“Metastatic melanoma was not included in the LY2382770 study, so it is possible that discordant results with fresolimumab (Morris et al. 2014) relate to the distinct tumor types investigated between the two studies, with melanoma being particularly sensitive to TGF-b inhibition.”
BackgroundResultInfluentialDecker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
“Galunisertib, a small molecule inhibitor of the TβRI-associated kinase, is in clinical trials for a number of different neoplastic indications (74–76) as is fresolimumab, a monoclonal antibody that blocks receptor ligand interaction of all TGF-β isoforms (77).”
BackgroundTransforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer
Jung, B., Staudacher, J. J., & Beauchamp, D. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.015 · Cited by 241
Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247
Chronic inflammation, cancer development and immunotherapy
Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., & Tang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040163 · Cited by 229
“For example, the TGF-β chelator GC1008 (also known as Fresolimumab) is one of the most characterized monoclonal anti-TGF-β1-3 antibodies, showing an acceptable safety and antitumor activity for patients with malignant melanoma or renal carcinoma in a phase one clinical trial (Morris et al., 2014; Liu, Ren and ten Dijk…”
BackgroundTransforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within
Baba, A. B., Rah, B., Bhat, G. R., Mushtaq, I., Parveen, S., Hassan, R., Hameed Zargar, M., & Afroze, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.791272 · Cited by 224
“Seven TGF- βRI (also known as activin-like receptor kinases {ALKs}, ALK1–7), five TGF-βRII (TGFBR2, BMPR2, ACVR2, ACVR2B, and AMHR2) and two TBRIIIs (betaglycan and endoglin) have been identified so far.”
BackgroundMartin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224
The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis
Dzobo, K., & Dandara, C. (2023) · Biomimetics · doi:10.3390/biomimetics8020146 · Cited by 171
TGF-beta: a master immune regulator
Larson, C., Oronsky, B., Carter, C. A., Oronsky, A., Knox, S. J., Sher, D., & Reid, T. R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1744568 · Cited by 210
“toacanthomas [110] not cardiovascular toxicities.”
In vitro cancer cell–ECM interactions inform in vivo cancer treatment
Holle, A. W., Young, J. L., & Spatz, J. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.007 · Cited by 213
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., Poizat, F., Bentobji, M., Azario-Cheillan, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1965 · Cited by 209
“Phase I studies with fresolimumab (human anti-TGFb mAb) are currently ongoing in melanoma and renal cell carcinoma (34) and our findings strongly suggest that clinical strategies targeting TGFb1 could be of major interest in prostate cancer.”
BackgroundPaz-Ares, L., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C.-C., Flor, M. J., Di Nicola, M., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 205
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Zahr, A. A., Salama, M. E., Carreau, N., Tremblay, D., Verstovsek, S., Mesa, R., Hoffman, R., & Mascarenhas, J. (2016) · Haematologica · doi:10.3324/haematol.2015.141283 · Cited by 196
Recent progress in TGF-β inhibitors for cancer therapy
Huang, C.-Y., Chung, C.-L., Hu, T.-H., Chen, J.-J., Liu, P.-F., & Chen, C.-L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111046 · Cited by 187
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx121 · Cited by 195
“While TGF-b signaling is known to promote myofibroblast differentiation, targeting this pathway in cancer is problematic because it also regulates tumor-suppressive functions, and ubiquitous inhibition has been shown to result in the development of cutaneous keratoacanthomas/squamous cell carcinomas (43,44).”
BackgroundTGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 174
“For efficacy, one melanoma patient achieves a partial response, and six patients are proven to have stable disease (NCT00356460) [13].”
BackgroundTherapeutic implications of cancer epithelial-mesenchymal transition (EMT)
Cho, E. S., Kang, H. E., Kim, N. H., & Yook, J. I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01108-7 · Cited by 180
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 175
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177
A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
Huynh, L., Hipolito, C., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 171
“Seven patients showed partial response, four patients developed reversible cutaneous keratoacanthomas and squamous-cell carcinomas and one patient acquired hyperkeratosis as unwanted side effects [68].”
BackgroundEmerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 172
Holle, A. W., Young, J. L., Vliet, K. J. V., Kamm, R. D., Discher, D. E., Janmey, P. A., Spatz, J. P., & Saif, M. T. A. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b04982 · Cited by 163
Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies
Tanabe, S., Quader, S., Cabral, H., & Ono, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00904 · Cited by 161
“Fresolimumab, a human anti-TGF-b monoclonal antibody was applied for the treatment in advanced malignant melanoma and renal cell carcinoma patients in Phase I study, which resulted in the acceptable safety and preliminary evidence of antitumor activity (Morris et al., 2014).”
BackgroundTherapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
Parichatikanond, W., Luangmonkong, T., Mangmool, S., & Kurose, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00034 · Cited by 174
Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., Somja, J., Delvenne, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1983 · Cited by 155
“Accordingly, the development of squamous cell carcinomas was observed in a phase 1 trial evaluating an anti–TGF-b antibody in melanoma patients (16, 17).”
BackgroundReassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy
Elebiyo, T., Rotimi, D. E., Evbuomwan, I. O., Maimako, R. F., Iyobhebhe, M. E., Ojo, O. A., Oluba, O. M., & Adeyemı, O. S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100620 · Cited by 201
Autophagy: controlling cell fate in rheumatic diseases
Rockel, J. S., & Kapoor, M. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.92 · Cited by 161
Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 163
Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Berzofsky, J. A., Hsu, F. J., & Guitart, J. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1653-0 · Cited by 145
“As reported separately [5, 6], 29 patients (28 MM, 1 RCC) were treated on study with fresolimumab.”
Self-citationTargeted cancer therapy – Are the days of systemic chemotherapy numbered?
Joo, W. D., Visintin, I., & Mor, G. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.09.008 · Cited by 143
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Lamora, A., Talbot, J., Mullard, M., Brounais-Le Royer, B., Redini, F., & Verrecchia, F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110096 · Cited by 131
“For example, GC-1008 (Fresolimumab, a humanized mAB against TGF-β) was developed and tested in Phase I/II clinical trials on patients with advanced malignant melanoma or renal carcinoma [99].”
MethodFibroblasts in the Tumor Microenvironment
Truffi, M., Sorrentino, L., & Corsi, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_2 · Cited by 154
Tissue-Specific Roles of NKT Cells in Tumor Immunity
Terabe, M., & Berzofsky, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01838 · Cited by 147
Self-citationDarragh, L. B., Oweida, A. J., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 137
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 129
“Moreover, several publications/abstracts released during the last 13 months reported the results of clinical trials involving (1) additional checkpoint blockers, such as the CTLA4-targeting mAb tremelimumab,(155-161) the PD-1-targeting mAb pidilizumab,(162,163) and the PD-L1-targeting mAbs MEDI4736,(156,159,164-168) M…”
BackgroundTargeting immunosuppression by TGF-β1 for cancer immunotherapy
de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 135
Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?
Tan, A. R., Alexe, G., & Reiss, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0184-1 · Cited by 124
Self-citationAdvances and challenges in kidney fibrosis therapeutics
Abbad, L., Estève, E., & Chatziantoniou, C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00934-5 · Cited by 147
“Adverse events observed after TGFβ inhibition include inflammation, toxicity and/or cytokine release syndrome 32,48 .”
Mechanisms of Normal Tissue Injury From Irradiation
Citrin, D. E., & Mitchell, J. B. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.04.001 · Cited by 131
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 144
Targeting inflammation as cancer therapy
Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 135
“In patients with advanced melanoma and RCC, fresolimumab displayed preliminary antitumor efficacy and acceptable safety profile at multiple doses [360].”
BackgroundInfluentialCancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 134
“Phase I trial data of another agent, fresolimumab, an anti-TGF-β monoclonal antibody, preliminarily suggested antitumor activity in melanoma and renal cell carcinoma [174].”
BackgroundThe Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression
Moreira, A. M., Pereira, J., Melo, S., Fernandes, M. S., Carneiro, P., Seruca, R., & Figueiredo, J. (2020) · Cells · doi:10.3390/cells9020394 · Cited by 118
Advances in phage display technology for drug discovery
Omidfar, K., & Daneshpour, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1037738 · Cited by 116
“treatment of idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis and cancer [113,114].”
BackgroundNew Developments on the Treatment of Liver Fibrosis
Koyama, Y., Xu, J., Liu, X., & Brenner, D. A. (2016) · Digestive Diseases · doi:10.1159/000445269 · Cited by 117
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy
Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 134
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Eser, P. Ö., & Janne, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.004 · Cited by 121
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
Cammareri, P., Rose, A., Vincent, D. F., Wang, J., Nagano, A., Libertini, S., Ridgway, R. A., Athineos, D., Coates, P. J., McHugh, A. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12493 · Cited by 125
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 124
Zhou, H., Wang, M., Zhang, Y., Su, Q., Xie, Z., Chen, X., Yan, R., Li, P., Li, T., Qin, X., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12294 · Cited by 128
Terabe, M., Ambrosino, E., Takaku, S., O'Konek, J. J., Venzon, D., Lonning, S., McPherson, J. M., & Berzofsky, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1066 · Cited by 112
Self-citationTGFΒ-induced transcription in cancer
Cantelli, G., Crosas-Molist, E., Georgouli, M., & Sanz-Moreno, V. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.009 · Cited by 111
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.